Last reviewed 2026-04-20 · How we verify

Elcitonin (ELCATONIN)

Phase 2 active Recombinant protein

Elcitonin (generic name: ELCATONIN) is a elcatonin drug. It is currently in Phase 2 development.

Elcatonin is thought to work by mimicking the action of certain natural peptides in the body.

Elcatonin (ELCATONIN) is a small molecule drug in the elcatonin class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of elcatonin is unclear, with unknown patent status and generic manufacturers. Further research is needed to determine its safety profile and potential therapeutic applications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ELCATONIN
Drug class	elcatonin
Modality	Recombinant protein
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In plain English, elcatonin is a synthetic version of a natural molecule that helps regulate various bodily functions. It's like a key that fits into a lock, allowing the body to respond in a specific way. By mimicking this natural molecule, elcatonin may help restore balance to the body's systems.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Elcitonin CI brief — competitive landscape report
Elcitonin updates RSS · CI watch RSS

Frequently asked questions about Elcitonin

What is Elcitonin?

Elcitonin (ELCATONIN) is a elcatonin drug.

How does Elcitonin work?

Elcatonin is thought to work by mimicking the action of certain natural peptides in the body.

What is the generic name of Elcitonin?

ELCATONIN is the generic (nonproprietary) name of Elcitonin.

What drug class is Elcitonin in?

Elcitonin belongs to the elcatonin class. See all elcatonin drugs at /class/elcatonin.

What development phase is Elcitonin in?

Elcitonin is in Phase 2.

Drug class: All elcatonin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing